VividQ has secured €6.7M in Series A funding to advance its holographic technology, enabling immersive AR experiences for various industries and applications.
Vandria, securing €27.6M, focuses on developing small-molecule mitophagy inducers to treat chronic diseases, and its lead program shows promise against neurodegenerative diseases.
Collection
[
|
...
]